In the haploidentical (haplo-) HSC transplantation (HSCT) (1) setting, NK cells play a central role in the successful therapy of high-risk leukemia, including adult acute myeloid leukemia (AML) and pediatric acute lymphoblastic leukemia. Thus, donor-derived allo-reactive NK cells can mediate efficient graft versus leukemia (GvL) activity without causing graft versus host disease (GvHD) (1, 2) .
In this context, it is important to investigate which type of graft manipulation or conditioning regimen may best support a rapid NK cell recovery and an efficient GvL response following HSCT.
In addition, it is necessary to define whether leukemia cells may impair the process of NK cell generation from HSC as well as the functional capability of mature NK cells. Experimental models of NK cell differentiation from CD34 + precursors provide an useful tool to analyze the molecular mechanisms involved in this process, under both physiological and pathological conditions. Notably,
in-vitro models of NK cell differentiation revealed that CD34 + cells may give rise also to group 3 innate lymphoid cells (ILC3), i.e. cells developmentally related to NK cells involved in defensive function and in lymphoid organ-inducing activity (3) (4) (5) .
In patients receiving HSCT, residual leukemic cells may interfere with the homeostasis of the bone marrow (BM) microenvironment. This effect could be exerted either through cell-to-cell contact or by the release of soluble factors (6, 7) . Moreover, the conditioning regimen and/or the occurrence of GvHD may sustain an inflammatory response in the BM which may further interfere with the normal hematopoiesis (8) . Notably, inflammation has been associated with promotion and progression of solid tumors, and may correlate with a poor prognosis (9) . Previous reports showed that serum levels of inflammatory cytokines or chemokines in AML patients may represent a prognostic factor and correlate with the clinical outcome (10, 11) . In this context, we have previously
shown that IL-8 may accelerate in-vitro-CD34 + cell differentiation towards CD161 + CD56 + (NK) cells thus suggesting that cytokines or chemokines, released during an inflammatory process, may influence NK cell differentiation (4) .
In the present study, in order to address whether AML blasts may affect NK cell development, we performed co-cultures of umbilical cord blood (UCB)-CD34 + cells in the absence (control=CTR) or in the presence of fresh leukemia blasts belonging to different FAB categories. Leukemia blasts were isolated from peripheral blood (PB) or BM of AML patients at diagnosis ( In G2 AML co-cultures, the ratio between CD56 + LFA-1 -CD94 -/NKG2A -cells (that may include both NK cell precursors and ILC3) (5) and CD56 Although we cannot exclude that other inhibitory factors may contribute to the modulation of NK cell differentiation, the finding that the numbers of CD161 + CD56 + cells recovered after treatment with neutralizing anti-IL-1β mAb were comparable to those of control cultures, suggested that IL-1β secreted by G2 AML plays a predominant role in the inhibitory effect and is responsible for the different effect in comparison with G1 AML.
Previous reports showed that mature NK cells isolated from peripheral blood of AML patients displayed a low expression of major activating NK receptors resulting in an impaired cytolytic activity (12) (13) (14) (15) . In this context, it has been shown that sera derived from human AML patients may contain microvesicles bearing TGF-β on their surface TGF-β, can induce modulation of the surface expression of activating NK receptors resulting in impairment of NK cell function (14) . This effect was not detectable under our experimental condition, most likely due to the use of a trans-well system in which microvescicles cannot diffuse from upper to lower chambers containing cell precursors. Notably, previous reports regarding inhibitory AML-mediated effect were focused on PB mature NK cells and not on differentiating NK cell precursors which may display a different susceptibility to AML-derived inhibitory factors. In this context, further experiments are in progress to better characterize the effects of AML and IL-1β on NK cell development. On the basis of our present data, it is conceivable that IL-1β produced by AML blasts may affect, proliferation of NK cell precursors at early stages of differentiation in the BM. Our present data are relevant in the context of HSCT in which IL-1β released by AML blasts, residual after the conditioning regimen, may alter the BM microenvironment displaying a bidirectional effect: by one hand, by limiting proliferation of NK cell precursors, it would impair NK cell recovery. On the other hand, IL-1β
would promote differentiation of CD34 + precursors towards mature, competent NK cells. However, due to the low numbers of NK cells recovered, the overall effect is likely to be detrimental, primarily in patients with high residual leukemic burden or in rapidly relapsing AML.
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